Introduction: Medulloblastoma (MB) is a heterogeneous tumor of the cerebellum that is divided into four main subgroups with distinct molecular and clinical features. Sonic Hedgehog MB (SHH-MB) is the most genetically understood and occurs predominantly in childhood. Current therapies consist of aggressive and non-targeted multimodal approaches that are often ineffective and cause long-term complications. These problems intensify the need to develop molecularly targeted therapies to improve outcome and reduce treatment-related morbidities. In this scenario, Hedgehog (HH) signaling, a developmental pathway whose deregulation is involved in the pathogenesis of several malignancies, has emerged as an attractive druggable pathway for SHH-MB therapy. Areas covered: This review provides an overview of the advancements in the HH antagonist research field. We place an emphasis on Smoothened (SMO) and glioma-associated oncogene homolog (GLI) inhibitors and immunotherapy approaches that are validated in preclinical SHH-MB models and that have therapeutic potential for MB patients. Literature from Pubmed and data reported on ClinicalTrial.gov up to August 2020 were considered. Expert opinion: Extensive-omics analysis has enhanced our knowledge and has transformed the way that MB is studied and managed. The clinical use of SMO antagonists has yet to be determined, however, future GLI inhibitors and multitargeting approaches are promising.

The SHH/GLI signaling pathway: a therapeutic target for medulloblastoma / Lospinoso Severini, L.; Ghirga, F.; Bufalieri, F.; Quaglio, D.; Infante, P.; Di Marcotullio, L.. - In: EXPERT OPINION ON THERAPEUTIC TARGETS. - ISSN 1472-8222. - 24:11(2020), pp. 1159-1181. [10.1080/14728222.2020.1823967]

The SHH/GLI signaling pathway: a therapeutic target for medulloblastoma

Lospinoso Severini L.;Ghirga F.;Bufalieri F.;Quaglio D.;Infante P.;Di Marcotullio L.
2020

Abstract

Introduction: Medulloblastoma (MB) is a heterogeneous tumor of the cerebellum that is divided into four main subgroups with distinct molecular and clinical features. Sonic Hedgehog MB (SHH-MB) is the most genetically understood and occurs predominantly in childhood. Current therapies consist of aggressive and non-targeted multimodal approaches that are often ineffective and cause long-term complications. These problems intensify the need to develop molecularly targeted therapies to improve outcome and reduce treatment-related morbidities. In this scenario, Hedgehog (HH) signaling, a developmental pathway whose deregulation is involved in the pathogenesis of several malignancies, has emerged as an attractive druggable pathway for SHH-MB therapy. Areas covered: This review provides an overview of the advancements in the HH antagonist research field. We place an emphasis on Smoothened (SMO) and glioma-associated oncogene homolog (GLI) inhibitors and immunotherapy approaches that are validated in preclinical SHH-MB models and that have therapeutic potential for MB patients. Literature from Pubmed and data reported on ClinicalTrial.gov up to August 2020 were considered. Expert opinion: Extensive-omics analysis has enhanced our knowledge and has transformed the way that MB is studied and managed. The clinical use of SMO antagonists has yet to be determined, however, future GLI inhibitors and multitargeting approaches are promising.
2020
Cancer; drug discovery; gli; hedgehog pathway; immunotherapy; medulloblastoma; multitarget; small molecules; smo; therapeutic target; Animals; Antineoplastic Agents; Cerebellar Neoplasms; Hedgehog Proteins; Humans; Immunotherapy; Medulloblastoma; Signal Transduction; Smoothened Receptor; Zinc Finger Protein GLI1; Molecular Targeted Therapy
01 Pubblicazione su rivista::01g Articolo di rassegna (Review)
The SHH/GLI signaling pathway: a therapeutic target for medulloblastoma / Lospinoso Severini, L.; Ghirga, F.; Bufalieri, F.; Quaglio, D.; Infante, P.; Di Marcotullio, L.. - In: EXPERT OPINION ON THERAPEUTIC TARGETS. - ISSN 1472-8222. - 24:11(2020), pp. 1159-1181. [10.1080/14728222.2020.1823967]
File allegati a questo prodotto
File Dimensione Formato  
Lospinoso-Severini_The-SHH/GLI_2020.pdf

accesso aperto

Tipologia: Documento in Post-print (versione successiva alla peer review e accettata per la pubblicazione)
Licenza: Creative commons
Dimensione 5.79 MB
Formato Adobe PDF
5.79 MB Adobe PDF

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1560340
Citazioni
  • ???jsp.display-item.citation.pmc??? 21
  • Scopus 36
  • ???jsp.display-item.citation.isi??? 34
social impact